Fenn C. Mathew

Array ( [id] => 1543322 [patent_doc_number] => 06372793 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-16 [patent_title] => 'Method for treatment of a neurological disease characterized by impaired neuromodulator function' [patent_app_type] => B1 [patent_app_number] => 09/642576 [patent_app_country] => US [patent_app_date] => 2000-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 11016 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/372/06372793.pdf [firstpage_image] =>[orig_patent_app_number] => 09642576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1536415 [patent_doc_number] => 06337328 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-01-08 [patent_title] => 'Bupropion metabolites and methods of use' [patent_app_type] => B1 [patent_app_number] => 09/640725 [patent_app_country] => US [patent_app_date] => 2000-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18119 [patent_no_of_claims] => 94 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/337/06337328.pdf [firstpage_image] =>[orig_patent_app_number] => 09640725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1521240 [patent_doc_number] => 06413999 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-07-02 [patent_title] => 'Treatment for acute physical insult to the central nervous system' [patent_app_type] => B1 [patent_app_number] => 09/640020 [patent_app_country] => US [patent_app_date] => 2000-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 5979 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/413/06413999.pdf [firstpage_image] =>[orig_patent_app_number] => 09640020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1298071 [patent_doc_number] => 06627625 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-09-30 [patent_title] => 'Treatment of behavioral disorders with -lactam compounds' [patent_app_type] => B1 [patent_app_number] => 09/640363 [patent_app_country] => US [patent_app_date] => 2000-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 70 [patent_no_of_words] => 27498 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/627/06627625.pdf [firstpage_image] =>[orig_patent_app_number] => 09640363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1561488 [patent_doc_number] => 06362173 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-03-26 [patent_title] => 'Methods for treating psychosis associated with cocaine addiction with glucocorticoid receptor antagonists' [patent_app_type] => B1 [patent_app_number] => 09/639377 [patent_app_country] => US [patent_app_date] => 2000-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13262 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/362/06362173.pdf [firstpage_image] =>[orig_patent_app_number] => 09639377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4273461 [patent_doc_number] => 06323239 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-11-27 [patent_title] => 'Treatment of addiction to ethanol and addictive-related behavior' [patent_app_type] => 1 [patent_app_number] => 9/635578 [patent_app_country] => US [patent_app_date] => 2000-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 20465 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/323/06323239.pdf [firstpage_image] =>[orig_patent_app_number] => 635578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1419737 [patent_doc_number] => 06514949 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-02-04 [patent_title] => 'Method compositions for treating the inflammatory response' [patent_app_type] => B1 [patent_app_number] => 09/634407 [patent_app_country] => US [patent_app_date] => 2000-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 9122 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/514/06514949.pdf [firstpage_image] =>[orig_patent_app_number] => 09634407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4305540 [patent_doc_number] => 06326385 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-12-04 [patent_title] => 'Methods for treating or preventing pain' [patent_app_type] => 1 [patent_app_number] => 9/631747 [patent_app_country] => US [patent_app_date] => 2000-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 7 [patent_no_of_words] => 13712 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/326/06326385.pdf [firstpage_image] =>[orig_patent_app_number] => 631747 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1416706 [patent_doc_number] => 06521639 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-02-18 [patent_title] => 'Percutaneously applicable preparation and suppository containing an antidementia medicament' [patent_app_type] => B1 [patent_app_number] => 09/628006 [patent_app_country] => US [patent_app_date] => 2000-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 2976 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/521/06521639.pdf [firstpage_image] =>[orig_patent_app_number] => 09628006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4397416 [patent_doc_number] => 06297280 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-10-02 [patent_title] => 'Composition and method for suppressing behavior problems of pets' [patent_app_type] => 1 [patent_app_number] => 9/619713 [patent_app_country] => US [patent_app_date] => 2000-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6628 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/297/06297280.pdf [firstpage_image] =>[orig_patent_app_number] => 619713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1504178 [patent_doc_number] => 06465458 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-10-15 [patent_title] => 'Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor' [patent_app_type] => B1 [patent_app_number] => 09/599213 [patent_app_country] => US [patent_app_date] => 2000-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9054 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/465/06465458.pdf [firstpage_image] =>[orig_patent_app_number] => 09599213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1566817 [patent_doc_number] => 06376501 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-04-23 [patent_title] => 'Type 2 helper T cell-selective immune response suppressors' [patent_app_type] => B1 [patent_app_number] => 09/582176 [patent_app_country] => US [patent_app_date] => 2000-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13555 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 309 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/376/06376501.pdf [firstpage_image] =>[orig_patent_app_number] => 09582176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1602810 [patent_doc_number] => 06432989 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-08-13 [patent_title] => 'Use of CRF antagonists to treat circadian rhythm disorders' [patent_app_type] => B1 [patent_app_number] => 09/587007 [patent_app_country] => US [patent_app_date] => 2000-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21095 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/432/06432989.pdf [firstpage_image] =>[orig_patent_app_number] => 09587007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1478660 [patent_doc_number] => 06451803 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-09-17 [patent_title] => 'N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders' [patent_app_type] => B1 [patent_app_number] => 09/583691 [patent_app_country] => US [patent_app_date] => 2000-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13684 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 886 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/451/06451803.pdf [firstpage_image] =>[orig_patent_app_number] => 09583691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4295664 [patent_doc_number] => 06197773 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-03-06 [patent_title] => 'N-acyl and N-aroyl aralkyl amides as serotonergic agents' [patent_app_type] => 1 [patent_app_number] => 9/584680 [patent_app_country] => US [patent_app_date] => 2000-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14256 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/197/06197773.pdf [firstpage_image] =>[orig_patent_app_number] => 584680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4314851 [patent_doc_number] => 06242465 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-06-05 [patent_title] => 'Compositions of optically pure (+) norcisapride' [patent_app_type] => 1 [patent_app_number] => 9/573423 [patent_app_country] => US [patent_app_date] => 2000-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9009 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/242/06242465.pdf [firstpage_image] =>[orig_patent_app_number] => 573423 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4384003 [patent_doc_number] => 06277887 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-08-21 [patent_title] => 'Methods for treating Parkinson\'s disease using optically pure (-)-bupropion' [patent_app_type] => 1 [patent_app_number] => 9/553029 [patent_app_country] => US [patent_app_date] => 2000-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5018 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/277/06277887.pdf [firstpage_image] =>[orig_patent_app_number] => 553029 [rel_patent_id] =>[rel_patent_doc_number] =>)